Pay in 4 interest-free payments of $33.55 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
TG101209 suppresses growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations
histological score and recruitment of dendritic cells to the site of inflammation
2017 Apr 3
It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking)
RO1138452 is a potent and selective antagonist for both human and rat IP receptors and that is possesses analgesic and anti-inflammatory potential
Atrasentan Hydrochloride K inhibitor 4 (trans) TG101209 suppresses growth of hematopoieticAtrasentan, also known as ABT 627, is a orally available ETA receptor antagonist with potential antineoplastic activity. As a selective antagonist of the endothelin A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin induced angiogenesis and tumor cell proliferation. Product information CAS Number: 195733 43 8 Molecular Weight: 547. 08 Formula: C29H39ClN2O6 Chemical Name: (2R,3R,4S) 4 (2H
US$ 17.17
US$ 17.21
US$ 45.00
US$ 9000.00
US$ 17.17
US$ 12000.00